Nivolumab Improves OS in Advanced Esophageal Cancer
October 1st 2019In the phase III ATTRACTION-3 study, nivolumab prolonged overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma, according to findings presented at the 2019 ESMO Congress.
Read More
Pembrolizumab Does Not Improve PFS Over Chemotherapy in Relapsed Malignant Pleural Mesothelioma
September 30th 2019Progression-free survival was not improved with pembrolizumab over chemotherapy in patients with malignant pleural mesothelioma, missing the primary endpoint of the phase III European Thoracic Oncology Platform PROMISE-meso trial presented at the 2019 ESMO Congress.
Read More
Risk of Progression or Death Reduced With Ivosidenib in Advanced Cholangiocarcinoma
September 30th 2019The risk of progression or death was reduced by 63% with ivosidenib as treatment of pretreated patients with IDH1-mutant advanced cholangiocarcinoma compared with placebo, according to data from the phase III ClarIDHy study that was presented at the 2019 ESMO Congress.
Read More
Abemaciclib Leads to Positive Benefit in Chinese Women With HR+ Breast Cancer
September 30th 2019CDK4/6 inhibitor abemaciclib plus endocrine therapy led to significant benefits in a population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer, according to data from 2 randomized trials presented at the 2019 ESMO Congress.
Read More
First-Line Atezolizumab/Chemotherapy Improves Outcomes in Metastatic Urothelial Cancer
September 30th 2019In patients with locally advanced or metastatic urothelial carcinoma, atezolizumab and chemotherapy improved median progression-free survival by 1.9 months compared with placebo and chemotherapy. However, no overall survival benefit was seen, according to results of the phase III IMvigor130 trial presented at the 2019 ESMO Congress.
Read More
Olaparib Improves rPFS in Heavily Pretreated HRR+ mCRPC
September 30th 2019In the phase III PROfound trial, olaparib improved radiographic progression-free survival compared to either abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer, who had homologous recombination repair gene alterations, according to findings presented at the 2019 ESMO Congress.
Read More
Selpercatinib Demonstrates Robust ORR in Thyroid Cancer
September 29th 2019Strong objective responses rates were seen in the phase I/II LIBRETTO trial, which studied RET inhibition with selpercatinib in patients with <em>RET</em>-mutant medullary thyroid cancer and for those with other <em>RET</em> fusion-positive thyroid cancer. The registrational findings were recently presented at ESMO Congress 2019.
Read More
Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer
September 29th 2019Three clinical trials presented at the 2019 ESMO Congress show that the tropomyosin receptor kinase inhibitor larotrectinib continues to show anti-tumor activity, including long-lasting objective responses and low toxicity, according to results from an integrated analysis.
Read More
Abemaciclib/Fulvestrant Demonstrates Overall Survival Benefit in HR+ Advanced Breast Cancer
September 29th 2019Results from the phase III MONARCH 2 trial showed that the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant improved overall survival by 9.4 months compared with fulvestrant and placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy, according to data presented at the 2019 ESMO Congress.
Read More
Subpar Concordance Seen With PD-L1 Assays in Advanced TNBC
September 29th 2019A subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression, by the SP142 immunohistochemistry assay had responses to atezolizumab and nab-paclitaxel, regardless of whether they had primary or metastatic disease, according to an exploratory biomarker substudy of IMpassion130.
Read More
HR+/HER2+ Breast Cancer PFS Improved With Abemaciclib
September 29th 2019Patients with advanced hormone receptor–positive, HER2-positive breast cancer had improved progression-free survival when receiving the CDK4/6 inhibitor abemaciclib and endocrine therapy with trastuzumab compared with trastuzumab and chemotherapy, according to findings from the randomized phase II monarcHER trial.<sup>1</sup>
Read More
OS Improvement Seen in Updated Results for Atezolizumab Combo in ES-SCLC
September 29th 2019Frontline atezolizumab plus carboplatin plus etoposide has shown an improvement in overall survival over placebo plus CP/ET in the treatment of patients with extensive-stage small cell lung cancer, according to updated results from the phase III IMpower133 trial.
Read More
OS Improved in Advanced HR+/HER2- Breast Cancer With Ribociclib/Fulvestrant
September 29th 2019Ribociclib with fulvestrant resulted in a clinically significant overall survival benefit compared with placebo in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to findings from the phase III MONALEESA-3 trial presented at the 2019 ESMO Congress.
Read More
Prolonged pCR Rates Seen in TNBC With Neoadjuvant Pembrolizumab and Chemotherapy
September 29th 2019Patients with early triple-negative breast cancer receiving neoadjuvant treatment with the combination of pembrolizumab and chemotherapy showed extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone in the phase III KEYNOTE-522 study.
Read More
Phase II Trial Shows Improved Survival in TNBC With Trilaciclib
September 29th 2019A randomized phase II study with patients with metastatic triple-negative breast cancer showed unexpected improved overall survival with the addition of trilaciclib, an investigational CDK4/6 inhibitor, to gemcitabine and cisplatin, even though the combination failed to meet a safety-related primary endpoint.
Read More
Overall Survival May Improve With the Addition of Atezolizumab to T-DM1 for HER2+ Breast Cancer
September 29th 2019The addition of atezolizumab to ado-trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive advanced breast cancer compared with T-DM1 alone, according to a second OS analysis of the phase II KATE2 trial presented at the 2019 ESMO Congress.
Read More
Responses Seen With Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer
September 29th 2019Enfortumab vedotin in combination with pembrolizumab induced objective responses in close to three-quarters of patients with cisplatin-ineligible locally advanced urothelial cancer, according to the results of a preliminary clinical evaluation.
Read More
Addition of Telaglenastat to Everolimus Extends PFS in Metastatic RCC
September 28th 2019Glutaminase inhibitor telaglenastat added to everolimus extends progression-free survival in patients with heavily pretreated advanced renal cell carcinoma compared with everolimus monotherapy, according to data from the phase II ENTRATA study presented at the 2019 ESMO Congress.
Read More
Olaparib Plus Bevacizumab Extends PFS as Frontline Maintenance in Ovarian Cancer
September 28th 2019The combination of olaparib and bevacizumab as frontline maintenance improved the median progression-free survival by 5.5 months over bevacizumab and placebo in patients with newly diagnosed, advanced ovarian cancer following prior treatment with a platinum-based chemotherapy plus bevacizumab, according to the phase III PAOLA-1 findings presented at the 2019 ESMO Congress.
Read More
Overall Survival Improved With Frontline Osimertinib in EGFR-Positive NSCLC
September 28th 2019Median overall survival was improved by 6.8 months with osimertinib as a first-line treatment for patients with metastatic, <em>EGFR</em>-mutant non–small cell lung cancer compared with erlotinib or gefitinib, despite crossover between arms, according to updated data from the phase III FLAURA study presented at the 2019 ESMO Congress.
Read More
Sacituzumab Govitecan Demonstrates Early Efficacy in Heavily Pretreated Metastatic Urothelial Cancer
September 28th 2019The antibody–drug conjugate sacituzumab govitecan induced objective responses in about 30% of heavily pretreated patients with metastatic urothelial carcinoma in initial results of a phase II trial that were presented at the 2019 ESMO Congress.
Read More
PFS Improved With Frontline Niraparib Maintenance in Ovarian Cancer
September 28th 2019Median progression-free survival was improved by 5.6 months with PARP inhibitor niraparib as first-line treatment for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy compared with placebo, according to data from the phase III PRIMA study presented at the ESMO Congress 2019 and simultaneously published in the <em>New England Journal of Medicine</em>.
Read More
Combination Cediranib Plus Olaparib Improves PFS in Platinum-Resistant Ovarian Cancer
September 28th 2019Cediranib in combination with olaparib demonstrated an improvement in progression-free survival when used as treatment for patients with platinum-resistant ovarian cancer (PROC). However, the difference in PFS compared with chemotherapy did not achieve statistical significance, according to a randomized trial presented at the 2019 ESMO Congress.
Read More
Combination of Atezolizumab and Bevacizumab Shows Early Efficacy in Unresectable HCC
September 28th 2019Atezolizumab in combination with bevacizumab induced objective responses in patients with unresectable hepatocellular carcinoma, according to results presented at the 2019 ESMO Congress from 2 small clinical trials.
Read More
Pemigatinib Induces Responses in Second-Line FGFR+ Cholangiocarcinoma
September 28th 2019An objective response rate of 35.5% was seen with treatment with pemigatinib, a selective oral inhibitor of FGFR1, 2, and 3, in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an <em>FGFR2 </em>rearrangement or fusion, according to findings from the phase II FIGHT-202 clinical trial presented at ESMO 2019.
Read More
Survival Benefit Seen With Atezolizumab in High PD-L1 NSCLC
September 28th 2019Single-agent atezolizumab improved overall survival in newly diagnosed patients with wild-type non–small cell lung cancer who had ≥50% expression of PD-L1 on tumor cells or ≥10% expression on tumor-infiltrating immune cells compared with platinum-based chemotherapy, according to the interim survival analysis of the phase III IMpower110 study.
Read More
Trend in OS Benefit Seen With Apalutamide in SPARTAN Trial for Nonmetastatic CRPC
September 27th 2019In the phase III SPARTAN trial, the combination of androgen receptor apalutamide and androgen deprivation therapy led to an overall survival OS benefit compared with placebo/androgen deprivation therapy in patients with nonmetastatic castration-resistant prostate cancer, based on the updated findings presented at the 2019 ESMO Congress.
Read More